Literature DB >> 6841304

Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration.

I V Weller, V Carreno, M J Fowler, J Monjardino, D Makinen, Z Varghese, P Sweny, H C Thomas, S Sherlock.   

Abstract

Six patients with hepatitis B virus (HBV) related chronic liver disease were treated with acyclovir, 5-15 mg/kg 8 hourly, given as an iv bolus or iv infusion over 1 h for up to 7 days. Two patients treated with 10 and 15 mg/kg 8 hourly showed a decrease in HBV-DNA polymerase and HBV-DNA when mean trough acyclovir plasma concentrations of 5.0 +/- 0.6 and 13.2 +/- 3.0 microM were attained. Inhibition of viral replication was not seen in patients treated with lower doses. Transient renal impairment was seen in two patients who received high dosage by the iv bolus mode of administration. This complication may be prevented by a high oral fluid intake or iv infusion of the drug over 1 h. Further study with acyclovir 15 mg/kg 8-hourly given as an iv infusion for longer periods is warranted.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6841304     DOI: 10.1093/jac/11.3.223

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

3.  Activities of arabinosyladenine monophosphate and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against ground squirrel hepatitis virus in vivo as determined by reduction in serum virion-associated DNA polymerase.

Authors:  D F Smee; S S Knight; A E Duke; W S Robinson; T R Matthews; P L Marion
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

4.  A conjugate of acyclovir monophosphate with lactosaminated albumin releases the phosphorylated drug in liver cells.

Authors:  L Fiume; C Busi; A Mattioli; C Spinelli; G Spinosa; A Bongini
Journal:  Naturwissenschaften       Date:  1989-02

5.  Antiviral treatment of chronic hepatitis B virus infection.

Authors:  D M Novick; H C Thomas
Journal:  J R Soc Med       Date:  1984-12       Impact factor: 5.344

6.  Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles.

Authors:  Zhi-Rong Zhang; Qin He
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 8.  A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies of hepatitis B virus carrier treatment: identification of factors influencing response rates.

Authors:  H C Thomas; L J Scully; A M Lever; I Yap; M Pignatelli
Journal:  Infection       Date:  1987       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.